- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03162289
Intermittent Fasting Accompanying Chemotherapy in Gynecological Cancers (FIT2)
Intermittent Fasting Accompanying Chemotherapy in Gynecological Cancers - a Randomized, Controlled, Two-armed Intervention Study
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Chemotherapy (CT) is a basic element in the therapy of gynecological oncologic diseases besides surgery, antibody therapy, anti-hormonal therapy and radiation. The chemotherapeutic intervention can be experienced physically and psychologically as a severe stress due to unwanted acute and also relevant long term side effects. It is even possible that because of severe side effects the CT can not be continued and main goals of the therapy like tumor reduction or elimination can not be achieved. Except of some medicinal approaches (such as antiemetics) or therapeutic exercise, not many therapeutic approaches are known to help reduce CT induced side effects. Against this background it is important to identify and scientifically evaluate new approaches to reduce the side effects of CT. The aim of this study is to verify the effectiveness of intermittent fasting as a potentially helpful supportive therapy in CT. In a prior pilot study of our institute with 34 breast- and ovarian cancer patients showed beneficial effects of an intermittent fasting of 72-84 h parallel to the application of the CT (manuscript submitted in Cancer Science).
The results of this confirmatory study are therefore of potentially high clinical relevance for all chemotherapeutically treated patients.
Long term goal: This study can lead to the improvement of tolerance and effectiveness of chemotherapeutic tumor therapy through accompanying intense nutritional therapy interventions. Beyond that it can be the starting point of a following multi-center randomized controlled study.
A large variety of animal experimental studies as well as three smaller pilot studies suggest that intermittent fasting can reduce the unwanted side effects of CT and enhance the quality of life. It is being speculated that the anti-tumor effect of fasting is enhanced through the reduction of the Insulin-like growth factor-1 (IGF-1) and mTOR as well as p53-signalling molecules (differential stress resistance).
But it is still unclear whether the possible beneficial effect that intermittent fasting shows can only be reached by subtotal caloric restriction or a significant reduction of the intake of animal proteins and refined sugar could also cause a similar decrease in IGF-1.
Against this background this confirmatory study aims to test the hypothesis that CT in the adjuvant and neoadjuvant treatment of breast- and ovarian cancer is better tolerable under intermittent fasting than under a normo-caloric vegan and sugar-reduced diet.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Berlin, Germany, 10117
- Brustzentrum Charite Campus Mitte
-
Berlin, Germany, 10967
- Vivantes Brustzentrum
-
Berlin, Germany, 13353
- Charité Virchow Klinikum
-
Berlin, Germany, 14163
- Brustzentrum Krankenhaus Waldfriede
-
Berlin, Germany, 14163
- Charité Hochschulambulanz für Naturheilkunde am Immanuel Krankenhaus
-
-
Baden-Württemberg
-
Freiburg im Breisgau, Baden-Württemberg, Germany, 79085
- Albert-Ludwigs-University of Freiburg
-
Ludwigsburg, Baden-Württemberg, Germany, 71640
- Klinikum Ludwigsburg
-
-
Brandenburg
-
Potsdam, Brandenburg, Germany, 14467
- Ernst-von-Bergmann Klinikum, Klinik für Gynäkologie und Geburtshilfe
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Diagnosed, gynecological, malignant tumor disease (non-metastatic ovarian or breast cancer).
Other inclusion criteria:
- Age 18-75 years
- Cancer is treated conventionally with an adjuvant or neo-adjuvant protocol with at least 4 CT cycles
The following CTs are considered for breast carcinoma:
- - (EC, Sparano) 4 x Epirubicin and Cyclophosphamide, followed by 12 cycles Paclitaxel weekly
- - (AC, Henderson) 4 x Doxorubicin, cyclophosphamide, followed by 4 cycles Docetaxel every three weeks
If the recruitment rate is not reached, further CT protocols can be accepted.
CT for patients with ovarian cancer: According to current protocols, at least 4 planned cycles. For the study a maximum of 8 cycles are considered (except therapy with Taxol).
Exclusion Criteria:
- Reduction in CT dose compared to usual dosage
- Excessive underweight (BMI <19kg / m2) or actual weight reduction > 3kg or > 5kg in the last 1 or 3 months.
- Pre-existing eating disorder (Anorexia nervosa, Bulimia)
- Renal insufficiency (creatinine> 2mg / dl)
- Severe disease or other disease with a significant reduction in mobility and overall vitality
- Diabetes mellitus
- No inclusion in other study protocol
- Lack of email address and Internet access (due to electronic CRF)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Fasting
60-72 h-modified fasting (36-48 h before and 24 h after chemotherapy)
|
Patients follow a modified fasting regime of 60-72 h (36-48 h before and 24 h after CT) with a dietary energy supply of 350-400kcal per day with vegetable juices during the first four cycles of CT.
During the rest of the CT cycles they will observe two days of caloric restriction (24 h before and after CT).
Between CTs a mainly vegetarian diet will be performed and the patients are encouraged to follow a pattern of time restricted feeding with 14 h fasting over night at least for six days a week.
The patients will receive an individual nutrition training by trained nutritionists.
|
Active Comparator: Vegan
60-72 h-vegan diet (36-48 h before and 24 h after chemotherapy)
|
Patients follow a 60-72 h vegan diet with sugar restriction (36-48 h before and 24 h after CT) during the first four cycles of CT.
During the rest of the CT cycles they will observe two days of vegan and sugar-restricted diet (24 h before and after CT).
Between CTs a mainly vegetarian diet will be performed.
The patients will receive an individual nutrition training by trained nutritionists.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
FACT-G
Time Frame: Date of inclusion (baseline), day -2 and +7 at each chemotherapy (CT) in triweekly cycles/-2 days at each CT in weekly cycles and +7 after the last weekly CT, 4 months after inclusion, 3 weeks after end of CT and 1, 2 and 3 years after inclusion
|
Summarized change of FACT-G score
|
Date of inclusion (baseline), day -2 and +7 at each chemotherapy (CT) in triweekly cycles/-2 days at each CT in weekly cycles and +7 after the last weekly CT, 4 months after inclusion, 3 weeks after end of CT and 1, 2 and 3 years after inclusion
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Complete remissions
Time Frame: From date of randomization until the date of surgery
|
Number of histologically proven complete remissions (ypT0ypN0 bzw.
ypT0/is) after neoadjuvant CT
|
From date of randomization until the date of surgery
|
Millar Payne classification
Time Frame: after surgery/histological examination, an average 6 months after intervention start
|
Histological classification according to Millar Payne scale
|
after surgery/histological examination, an average 6 months after intervention start
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Trial outcome index score (TOI)
Time Frame: Date of inclusion (baseline), day -2 and +7 at each chemotherapy (CT) in triweekly cycles/-2 days at each CT in weekly cycles and +7 after the last weekly CT, 4 months after inclusion, 3 weeks after end of CT and 1, 2 and 3 years after inclusion
|
TOI
|
Date of inclusion (baseline), day -2 and +7 at each chemotherapy (CT) in triweekly cycles/-2 days at each CT in weekly cycles and +7 after the last weekly CT, 4 months after inclusion, 3 weeks after end of CT and 1, 2 and 3 years after inclusion
|
Total AC (FACT-B/FACT-O)
Time Frame: Date of inclusion (baseline), day -2 and +7 at each CT in triweekly cycles/-2 days at each CT in weekly cycles and +7 after the last weekly CT, 4 months after inclusion, 3 weeks after end of CT and 1, 2 and 3 years after inclusion
|
According to kind of cancer (breast cancer/ ovarian cancer)
|
Date of inclusion (baseline), day -2 and +7 at each CT in triweekly cycles/-2 days at each CT in weekly cycles and +7 after the last weekly CT, 4 months after inclusion, 3 weeks after end of CT and 1, 2 and 3 years after inclusion
|
FACIT-F
Time Frame: Date of inclusion (baseline), day -2 and +7 at each CT in triweekly cycles/-2 days at each CT in weekly cycles and +7 after the last weekly CT, 4 months after inclusion, 3 weeks after end of CT and 1, 2 and 3 years after inclusion
|
Fatigue
|
Date of inclusion (baseline), day -2 and +7 at each CT in triweekly cycles/-2 days at each CT in weekly cycles and +7 after the last weekly CT, 4 months after inclusion, 3 weeks after end of CT and 1, 2 and 3 years after inclusion
|
FACT-Tax,FACT/GynecologicOncologyGroup-Ntx
Time Frame: Date of inclusion (baseline), day -2 and +7 at each CT in triweekly cycles/-2 days at each CT in weekly cycles and +7 after the last weekly CT, 4 months after inclusion, 3 weeks after end of CT and 1, 2 and 3 years after inclusion
|
Specific chemotherapy induced effects on quality of life and neurologic symptoms
|
Date of inclusion (baseline), day -2 and +7 at each CT in triweekly cycles/-2 days at each CT in weekly cycles and +7 after the last weekly CT, 4 months after inclusion, 3 weeks after end of CT and 1, 2 and 3 years after inclusion
|
Chemotherapy-Induced Peripheral Neuropathy Assessment Tool
Time Frame: Date of inclusion (baseline), day -2 and +7 at each CT in triweekly cycles/-2 days at each CT in weekly cycles and +7 after the last weekly CT, 4 months after inclusion, 3 weeks after end of CT and 1, 2 and 3 years after inclusion
|
Chemotherapy-Induced Peripheral Neuropathy Assessment Tool
|
Date of inclusion (baseline), day -2 and +7 at each CT in triweekly cycles/-2 days at each CT in weekly cycles and +7 after the last weekly CT, 4 months after inclusion, 3 weeks after end of CT and 1, 2 and 3 years after inclusion
|
Hospital Anxiety and Depression Scale
Time Frame: Date of inclusion (baseline), day -2 and +7 at each CT in triweekly cycles/-2 days at each CT in weekly cycles and +7 after the last weekly CT, 4 months after inclusion, 3 weeks after end of CT and 1, 2 and 3 years after inclusion
|
Hospital Anxiety and Depression Scale
|
Date of inclusion (baseline), day -2 and +7 at each CT in triweekly cycles/-2 days at each CT in weekly cycles and +7 after the last weekly CT, 4 months after inclusion, 3 weeks after end of CT and 1, 2 and 3 years after inclusion
|
Side effects of CT
Time Frame: Date of inclusion (baseline), day -2 and +7 at each CT in triweekly cycles/-2 days at each CT in weekly cycles and +7 after the last weekly CT, 4 months after inclusion, 3 weeks after end of CT and 1, 2 and 3 years after inclusion
|
Likert scales
|
Date of inclusion (baseline), day -2 and +7 at each CT in triweekly cycles/-2 days at each CT in weekly cycles and +7 after the last weekly CT, 4 months after inclusion, 3 weeks after end of CT and 1, 2 and 3 years after inclusion
|
Weight
Time Frame: Timing varies according to individual therapy plan, Date of inclusion (baseline) and up to 3 years after inclusion
|
Documentation according to the standard documentation rules of the German Tumour Centres Work Group, Weight in kilograms
|
Timing varies according to individual therapy plan, Date of inclusion (baseline) and up to 3 years after inclusion
|
BMI
Time Frame: Timing varies according to individual therapy plan, Date of inclusion (baseline) and up to 3 years after inclusion
|
Documentation according to the standard documentation rules of the German Tumour Centres Work Group, BMI in kg/m^2
|
Timing varies according to individual therapy plan, Date of inclusion (baseline) and up to 3 years after inclusion
|
Blood panel
Time Frame: Timing varies according to individual therapy plan, Date of inclusion (baseline) and up to 3 years after inclusion
|
Documentation according to the standard documentation rules of the German Tumour Centres Work Group, units auf measure according to SI units
|
Timing varies according to individual therapy plan, Date of inclusion (baseline) and up to 3 years after inclusion
|
Blood values for liver function
Time Frame: Timing varies according to individual therapy plan, Date of inclusion (baseline) and up to 3 years after inclusion
|
Documentation according to the standard documentation rules of the German Tumour Centres Work Group, units auf measure according to SI units
|
Timing varies according to individual therapy plan, Date of inclusion (baseline) and up to 3 years after inclusion
|
Blood values for renal function (Krea, Hst.)
Time Frame: Timing varies according to individual therapy plan, Date of inclusion (baseline) and up to 3 years after inclusion
|
Documentation according to the standard documentation rules of the German Tumour Centres Work Group, units auf measure according to SI units
|
Timing varies according to individual therapy plan, Date of inclusion (baseline) and up to 3 years after inclusion
|
IGF-1, Insulin, Blood glucose
Time Frame: Baseline, after 4 months and before each of the first 4 CTs meaning approx week 1,4,7 and 10 after intervention start
|
Explorative measurements in blood samples in subgroup of 20 patients
|
Baseline, after 4 months and before each of the first 4 CTs meaning approx week 1,4,7 and 10 after intervention start
|
Long-term explorative measurements: frequency of recurrence
Time Frame: 1, 2 and 3 years after baseline
|
Information taken from the documentation of the treatment, visits and questionnaires
|
1, 2 and 3 years after baseline
|
Long-term explorative measurements: e.g. polyneuropathy, cardiomyopathy
Time Frame: 1, 2 and 3 years after baseline
|
Information taken from the documentation of the treatment, visits, questionnaires and interview
|
1, 2 and 3 years after baseline
|
ketone bodies
Time Frame: Baseline, after 4 months and before each of the first 4 CTs meaning approx week 1,4,7 and 10 after intervention start
|
Explorative measurements in capillary blood, only in subpopulation of n=20
|
Baseline, after 4 months and before each of the first 4 CTs meaning approx week 1,4,7 and 10 after intervention start
|
Elective items of the "Common Terminology Criteria for Adverse Events (CTCAE)
Time Frame: Baseline, 3 weeks after end of CT, 1,2,3 years after baseline
|
Elective items of the "Common Terminology Criteria for Adverse Events (CTCAE)"
|
Baseline, 3 weeks after end of CT, 1,2,3 years after baseline
|
Qualitative interviews in focus groups
Time Frame: Baseline, 6 months
|
Qualitative interviews in focus groups
|
Baseline, 6 months
|
Collaborators and Investigators
Investigators
- Principal Investigator: Andreas Michalsen, Prof. Dr., Study Principal Investigator Charite
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyActive, not recruitingStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
University of WashingtonTerminatedBreast Cancer | Breast Cancer Stage I | Breast Cancer Stage II | Breast Cancer Stage III | Breast Cancer Stage IIB | Breast Cancer Stage IIA | Breast Cancer Stage IIIA | Breast Cancer Stage IIIB | Breast Cancer Stage IIIcUnited States
-
CelgeneCompletedBreast Cancer | Metastatic Breast Cancer | Stage IV Breast Cancer | Triple-negative Breast Cancer | Recurrent Breast Cancer | Breast Tumor | Cancer of the Breast | Triple-negative Metastatic Breast Cancer | Estrogen Receptor- Negative Breast Cancer | HER2- Negative Breast Cancer | Progesterone Receptor- Negative...United States, United Kingdom, Italy, Germany, Spain, Canada, Portugal, Australia, Austria, Greece, Brazil, France
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedHER2-positive Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast...United States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Susan G. Komen Breast Cancer FoundationCompletedStage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
Ohio State University Comprehensive Cancer CenterCompletedStage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Stage III Breast CancerUnited States
Clinical Trials on Fasting
-
Kasr El Aini HospitalCompleted
-
Charite University, Berlin, GermanyKarl and Veronica Carstens FoundationTerminatedFertility Issues | Fertility Disorders | IVF | Sub Fertility, Female | Sub-fertilityGermany
-
Cairo UniversityWithdrawnPolycystic Ovary Syndrome | InfertilityEgypt
-
Shiraz University of Medical SciencesCompletedCoronary Artery DiseaseIran, Islamic Republic of
-
Charite University, Berlin, GermanyCompletedCancer | Fasting | NeoplasiaGermany
-
HealthPartners InstituteCompletedDiabetes Mellitus | Hyperlipidemia | Normal Glucose MetabolismUnited States
-
H. Lee Moffitt Cancer Center and Research InstituteNot yet recruitingPancreatitis | Pancreatitis, Chronic | Pancreatitis, Acute | Pancreas Disease | Acute Recurrent PancreatitisUnited States
-
Nottingham Trent UniversityLoughborough UniversityCompleted
-
Universidade de Passo FundoFederal University of Rio Grande do SulCompleted
-
Mahidol UniversityHealth Systems Research InstituteEnrolling by invitationWeight Loss | Obese | Intermittent Fasting | Behavioral Economic | HOMA-IRThailand